Theravance Biopharma, Inc. TBPH

What this company does

It relies on a network of third-party contract manufacturing organizations to produce active pharmaceutical ingredients and drug products. In the US, Viatris leads commercialization of YUPELRI and the company co-promotes the product under a profit and loss sharing arrangement of 65% to Viatris and 35% to it, while outside the US, excluding China and adjacent territories, Viatris is responsible for development and commercialization and pays a tiered royalty on net sales at rates ranging from low double-digits to mid-teens. As of December 31, 2025, it had 90 employees, of whom 79 were based in the US and 11 were based in Dublin, Ireland. Theravance Biopharma was incorporated in the Cayman Islands in July 2013 under the name Theravance Biopharma, Inc., and began operating as an independent, publicly traded company on June 2, 2014 following a spin-off from Innoviva, Inc.

Written from the business description in THERAVANCE BIOPHARMA, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 23 March 2026. Every sentence was checked against that document before publication.